EZH2 Protein Expression in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and Prognosis
Conclusion:
In our study of TNBC treated with NAC, high EZH2 expression in pretherapy core biopsies was significantly associated with metastatic recurrence independent of RCB. The potential value of EZH2 as a biomarker to improve stratification of outcome after NAC should be explored further.
Source: Applied Immunohistochemistry and Molecular Morphology - Category: Chemistry Tags: Research Articles Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemistry | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Stem Cell Therapy | Stem Cells | Study